Skip to Content

Subcutaneous Injection of Therapeutic Monoclonal Antibodies

Team Members:
  • Truc Nguyen
  • Daniel Adler
  • Catherine Bernstein
  • Alexia Haralambous
  • Jonathan Hunt
  • Thomas Nguyen
  • Antonio Spina
  • Lucia Tellez
  • Mitch Zhao, PhD
  • Janssen Research & Development


In order to facilitate subcutaneous delivery of therapeutic monoclonal antibody (mAb) suspensions, we developed Syr-Q, an injection device. Syr-Q resuspends sedimented mAb particles that would otherwise clog the needle, leading to incomplete drug delivery. Syr-Q features an eccentric rotating mass (ERM), which adequately resuspends sedimented mAb particles by generating vibrations through centripetal acceleration. The ERM is attached to a timing circuit, which resuspends the particles for 15 seconds before shutting off, which allows the patient to safely self-administer the medication. Preliminary testing has shown that our resuspension mechanism is capable of decreasing the injection force from 80 N to less than 25 N, with statistical significance of p < 0.0005. Our proof of concept will allow for the self-administration of mAb therapeutics at home, saving on clinical resources and facilities, and will allow for the delivery of drugs that are currently undeliverable subcutaneously.

Read the Johns Hopkins University privacy statement here.